Tagged with patients

China PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews, giving an exclusive glimpse into what is currently at the top of the minds of pharma country managers in China.…

Sweden We recently analysed the contents of 20 interviews conducted with country managers at multinational pharma companies in Sweden and found some underlying words and themes present in the majority of the interviews (see above for the full wordcloud). This is an exclusive glimpse into what is currently at the top…

Sweden Thanks to the cooperation of its citizens, Sweden boasts a comprehensive patient registry of electronic health records. Multinational pharma companies increasingly look to these registries to collect real-world evidence, which helps them develop more innovative treatments.     Combining data from the disease registry with the healthcare databases allows us…

Puerto Rico Puerto Rico has long been known for its pharma manufacturing prowess, but multinational companies are increasingly looking to conduct clinical trials there, thanks to strong institutional support, a strong example set by R&D-focused university spin-off companies, and the island’s unique ethnic profile.   The Hispanic population has been historically underrepresented…

USA David Mitchell, founder of Patients for Affordable Drugs, looks at the US pharmaceutical industry from the patients’ perspective.   This is both a hopeful and terrifying time to be a patient in the USA What are the key factors and trends shaping the pharmaceutical sector in the US? I have…

France Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and the broader role of patient associations within the French healthcare ecosystem.   In France, 20 million people are suffering from…

Opinion Deloitte’s Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019’s industry trends.   For companies to address mounting pressures, a digital-first mindset will be required to make business operations more efficient and bring transformational therapies to the market.   Digital…

Opinion Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan’s 2019 Health Care Investor Conference, one of the biggest events in the life sciences calendar and a fantastic indicator of what is to come in healthcare for the year ahead. Here, Crean gives us the inside scoop. …

Opinion After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here Monica discusses the incredibly low rate of treatment options for…

Patients The Director General of EFPIA (European Federation of Pharmaceutical Industries and Associations) discusses what they are doing to put patients at the forefront of their business.      Actively listening to patient experiences, patient challenges and exchanging insights must shape how EFPIA develops its thinking, its dialogue with others, its policy…

Malaysia American medtech giant Baxter and pan-Asian healthcare service provider Zuellig Pharma have been collaborating in Malaysia to increase the quality and quantity of care that can be given to patients in their own homes, generating significant cost-savings for the healthcare system and increasing patient-centricity.   “[Home care] reduces costs significantly,…

Patients There are around 2 billion people in the world that do not have access to the medicines they need. This week the 2018 Access to Medicine Index was published revealing that there is a handful of pharmaceutical companies developing the bulk of urgently needed new medicines for the poor. The…